Results 171 to 180 of about 235,143 (310)

Pernicious Anaemia

open access: yesAutoimmunity, 2004
Ban-Hock, Toh, Frank, Alderuccio
openaire   +2 more sources

American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel

open access: yesArthritis &Rheumatology, EarlyView.
Objective Vacuoles E1 enzyme X‐linked autoinflammatory somatic syndrome (VEXAS) is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. VEXAS presents with a combination of inflammatory and hematologic manifestations, leading to increased morbidity and mortality.
Arsene Mekinian   +111 more
wiley   +1 more source

Pernicious Anaemia

open access: yesInternational Journal of Clinical Practice, 1957
openaire   +2 more sources

Case‐Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease

open access: yesArthritis &Rheumatology, EarlyView.
Interstitial lung disease (ILD) is an important complication of systemic sclerosis (SSc), with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to US Food and Drug Administration–approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of ILDs of other systemic autoimmune
Nina Goldman   +2 more
wiley   +1 more source

Neonatal Aplastic Anaemia and Fanconi's Anaemia [PDF]

open access: yesArchives of Disease in Childhood, 1963
E M, O'Neill, S, Varadi
openaire   +2 more sources

Impact evaluation of a population-based 'Screen and Treat for Anaemia Reduction (STAR)' strategy: a cluster randomised trial in rural Telangana, India. [PDF]

open access: yesBMJ Glob Health
Pullakhandam R   +8 more
europepmc   +1 more source

Comparative Efficacy and Safety of Anakinra and Canakinumab in Patients With VEXAS Syndrome: An International Multicenter Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective The aim of this study was to compare differences in clinical response, drug survival, and adverse event rates between anakinra and canakinumab in VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic) syndrome. Methods This multicenter international study includes patients with VEXAS from France, Israel, and Italy treated with ...
Tali Eviatar   +35 more
wiley   +1 more source

Home - About - Disclaimer - Privacy